PT  - JOURNAL ARTICLE
AU  - M. L. Disis
AU  - S. E. Rivkin
AU  - A. Baron
AU  - M. Markman
AU  - D. Connolly
AU  - F. Ueland
AU  - E. Kohn
AU  - E. Trimble
AU  - J. S. Berek
TI  - Progress in ovarian cancer research: Proceedings of the 5th Biennial Ovarian Cancer Research Symposium
AID  - 10.1136/ijgc-00009577-200603000-00001
DP  - 2006 Mar 01
TA  - International Journal of Gynecologic Cancer
PG  - 463--469
VI  - 16
IP  - 2
4099  - http://ijgc.bmj.com/content/16/2/463.short
4100  - http://ijgc.bmj.com/content/16/2/463.full
SO  - Int J Gynecol Cancer2006 Mar 01; 16
AB  - Ovarian cancer remains the most lethal gynecological malignancy. The 5th Biennial Symposium overviewed the progress of ovarian cancer research over the last few years. Molecularly based technologies have allowed the identification of multiple biomarkers to aid in ovarian cancer diagnosis and treatment. Furthermore, data analysis systems evaluating the behavior of these markers have been designed. Therapeutic use of ovarian cancer protein markers has been fueled by the development of animal models that more closely simulate the pathogenesis of ovarian cancer, and multiple new therapies are being developed that may have impact against the disease. Finally, the design of clinical trials both for ovarian cancer treatment and prevention are key in advancing the science of ovarian cancer into the clinic. The need for strategies that would optimize patient participation in clinical trials is paramount.